Search

Your search keyword '"Verdonck, P."' showing total 122 results

Search Constraints

Start Over You searched for: Author "Verdonck, P." Remove constraint Author: "Verdonck, P." Journal blood Remove constraint Journal: blood
122 results on '"Verdonck, P."'

Search Results

1. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

2. Favorable effect of priming with granulocyte colony-stimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine

3. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

4. Autologous peripheral blood stem cell transplantation for acute myeloid leukemia

5. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

6. Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study

7. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

8. The graft-versus-leukemia effect using matched unrelated donors is not superior to HLA-identical siblings for hematopoietic stem cell transplantation

9. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

10. Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: a prospective sibling donor versus no-donor comparison

11. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

12. Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia

13. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL: a prospective randomized HOVON trial

14. Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+NHL: a prospective randomized HOVON trial

15. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

16. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?

17. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

18. Intensified 12-week CHOP (I-CHOP) plus G-CSF compared with standard 24-week CHOP (CHOP-21) for patients with intermediate-risk aggressive non-Hodgkin lymphoma: a phase 3 trial of the Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON)

19. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation

20. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation

21. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

22. Anti-CD20 monoclonal antibody treatment in 6 patients with therapy-refractory chronic graft-versus-host disease

23. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

24. The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients

25. High EVI1 expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

26. High EVI1expression predicts poor survival in acute myeloid leukemia: a study of 319 de novo AML patients

27. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse

28. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

29. Donor lymphocyte infusion for relapsed chronic myelogenous leukemia: prognostic relevance of the initial cell dose

30. Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse

31. Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

32. Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

33. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT

34. Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT

35. von Willebrand Factor Proteolysis Is Deficient in Classic, but not in Bone Marrow Transplantation–Associated, Thrombotic Thrombocytopenic Purpura

36. von Willebrand Factor Proteolysis Is Deficient in Classic, but not in Bone Marrow Transplantation–Associated, Thrombotic Thrombocytopenic Purpura

37. A Fixed Low Number of T Cells in HLA-Identical Allogeneic Bone Marrow Transplantation

38. Cytomegalovirus Infection Causes Delayed Platelet Recovery After Bone Marrow Transplantation

39. Allogeneic bone marrow transplantation with a fixed low number of T cells in the marrow graft [see comments]

40. T lymphocyte repopulation and differentiation after bone marrow transplantation. Early shifts in the ratio between T4+ and T8+ T lymphocytes correlate with the occurrence of acute graft-versus-host disease

41. A fixed low number of T cells in HLA-identical allogeneic bone marrow transplantation

42. Allogeneic Bone Marrow Transplantation for Low-Grade Lymphoma

43. Allogeneic bone marrow transplantation versus autologous stem cell transplantation in multiple myeloma: a retrospective case-matched study from the European Group for Blood and Marrow Transplantation

44. Intensive cytotoxic therapy followed by autologous bone marrow transplantation for non-Hodgkin's lymphoma of high-grade malignancy

45. Delay in Platelet Recovery After Bone Marrow Transplantation: Impact of Cytomegalovirus Infection

46. Autologous Bone Marrow Transplantation for Acute Myelocytic Leukemia in First Remission: A European Survey of the Role of Marrow Purging

47. Intensive Cytotoxic Therapy Followed by Autologous Bone Marrow Transplantation for Non-Hodgkin's Lymphoma of High-Grade Malignancy

48. T Lymphocyte Repopulation and Differentiation After Bone Marrow Transplantation. Early Shifts in the Ratio Between T4+and T8+T Lymphocytes Correlate With the Occurrence of Acute Graft-Versus-Host Disease

49. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia [see comments]

50. Recovery of T Cell Subsets After Autologous Bone Marrow Transplantation Is Mainly due to Proliferation of Mature T Cells in the Graft

Catalog

Books, media, physical & digital resources